Search
Alzheimer's Disease Paid Clinical Trials in Connecticut
A listing of 17 Alzheimer's Disease clinical trials in Connecticut actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 17 of 17
The state of Connecticut currently has 17 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Neurologic Stem Cell Treatment Study
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Stem Cells, Westport, Connecticut
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Recruiting
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/22/2025
Locations: Yale University PET Center, New Haven, Connecticut
Conditions: Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
Neurophysiological Benefits of Live Music for Early Alzheimer's Patients and Their Caregivers
Recruiting
This study aims to investigate the neurophysiological effects of live music on individuals with early Alzheimer's Disease (AD), dementia, and/or mild cognitive impairment (MCI) and their caregivers. Heart rate (HR), heart rate variability (HRV), and brain activity will be measured as participant-caregiver dyads listen to preferred and improvised music performed by professional musicians. Investigators will leverage various measurement techniques including, but not limited to, electroencephalogra... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/15/2025
Locations: Firehouse 12 Studios, New Haven, Connecticut +1 locations
Conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/29/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Alzheimer's Disease
13 - 17 of 17